Quadrant Capital Group LLC Vir Biotechnology, Inc. Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 3,326 shares of VIR stock, worth $32,262. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,326
Previous 4,102
18.92%
Holding current value
$32,262
Previous $36,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VIR
# of Institutions
214Shares Held
85.2MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$162 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$159 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$127 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$54.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$34.7 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.29B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...